Posts

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Eli Lilly partners with Oura to support GLP-1 patients via smart‑ring tools

on

Chai Discovery raises $400M Series C for AI molecule models used by Lilly, Novartis and Pfizer

on

Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

Lilly bolsters non‑opioid pain portfolio with 4E Therapeutics buy

on

Lilly Offers Up to $1B for Alzheimer's Drug

on

Roche bets $700M upfront on Nurix’s late‑phase BTK degrader to tee up Lilly showdown

on

Obesity care startup Ilant Health raises $15M Series A for AI‑supported precision‑obesity‑care platform

on

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update

on

ASCO 2026: Lilly’s Retevmo tied to dramatic outcomes in early‑stage RET fusion‑positive lung cancer

on

Lilly signs up to $1.26B deal for Hanmi's GLP‑2 drug sonefpeglutide for short bowel syndrome and other indications

on

ASCO 2026: A battle of bispecifics, Eli Lilly’s big win and more

on

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

on

Roche Secures Second CE Mark for Eli Lilly-Co-Developed Alzheimer's Blood Test pTau217 in Europe

on

Eli Lilly Invests Additional $4.5B in Indiana Manufacturing Facilities at LEAP District

on

Eli Lilly Touts Strong Early Launch of Foundayo Obesity Pill Despite Lagging Behind Novo's GLP-1

on

Profluent and Eli Lilly Announce $2.25 Billion Partnership for AI-Designed Genetic Medicines

on